ImmunoForge Sets the Stage for Global Licensing at JPMorgan Healthcare Conference 2026
ImmunoForge Co., Ltd. announces a strategic push at the 2026 JPMorgan Healthcare Conference in San Francisco, focusing on global out-licensing of its Phase 2 assets PF1801 and PF1804. With co-CEOs and a mission to accelerate clinical progress, ImmunoForge plans to engage directly with leading multinational pharmaceutical companies to expedite U.S. entry and broaden access to its innovative oncology portfolio.
Strategic Objective: Global Out-Licensing of PF1801 and PF1804
The company is prioritizing licensing partnerships that can fast-track PF1801 and PF1804 through late-stage development and into clinical use. PF1801 and PF1804 represent distinct modalities in ImmunoForge’s pipeline, each with potential to address unmet needs in cancer therapy. The goal is to secure robust collaborations that provide clinical, regulatory, and commercial support across key markets, while preserving patient access and post-approval value creation.
Why JPM 2026 Is the Right Forum
The JP Morgan Healthcare Conference remains a pivotal venue for deal-making in biotech. ImmunoForge seeks to leverage high-level meetings with decision-makers from global big pharma, biotechs, and venture groups. The company will showcase scientific milestones, regulatory pathways, and strategic plans for PF1801 and PF1804, framing licensing discussions around accelerated timelines, scalable manufacturing, and competitive differentiation.
Accelerating U.S. Clinical Entry Through Global Partnerships
A core objective is to streamline U.S. clinical entry by partnering with established U.S. and global pharmaceutical entities. ImmunoForge will present a clear pathway for PF1801 and PF1804, including proposed trial designs, anticipated endpoints, and regulatory strategies aligned with U.S. FDA expectations. By aligning with global partners, the company aims to shorten development timelines, share risk, and optimize market access across major regions.
What Partners Can Expect
Potential collaborators can anticipate a collaborative framework that supports co-development, co-commercialization, or out-licensing arrangements tailored to each partner’s portfolio strategy. ImmunoForge emphasizes transparent milestones, binding exclusivity windows, and clearly defined exit strategies to ensure mutual value. In addition to upfront payments, potential deals could include milestones tied to PF1801 and PF1804’s clinical progress and regulatory approvals.
About ImmunoForge
ImmunoForge is a Seoul-based biotech focused on advancing cancer therapies through innovative immune-oncology platforms. With a patient-centric mission and a robust early-stage pipeline, the company seeks strategic collaborations that enable rapid progress from Phase 2 assets to patient access. The San Francisco meetings at JPMorgan are designed to catalyze these partnerships and expand the company’s global footprint.
Next Steps for Interested Partners
Global pharmaceutical companies, biotech developers, and investment groups attending JPM 2026 are encouraged to seek out ImmunoForge principals to discuss PF1801 and PF1804 licensing opportunities. The company will provide detailed development plans, safety and efficacy data, and regulatory timelines to aligned partners, aiming to close meaningful partnerships that benefit patients and stakeholders alike.
